By Chris Holman
Amgen Inc. v. Sandoz Inc., 2023 WL 2994166, - 4th - (Fed.Cir.Apr. 19, 2023)
In 2019, Amgen acquired worldwide rights to apremilast (OTEZLA) from Celgene $13.4 billion in cash, in connection with Celgene's merger with Bristol-Myers Squibb.Apremilast was the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and in 2020 apremilast generated $2.2 billion for Amgen.
Amgen Inc. v. Sandoz Inc., 2023 WL 2994166, - 4th - (Fed.Cir.Apr. 19, 2023)
In 2019, Amgen acquired worldwide rights to apremilast (OTEZLA) from Celgene $13.4 billion in cash, in connection with Celgene's merger with Bristol-Myers Squibb.Apremilast was the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and in 2020 apremilast generated $2.2 billion for Amgen.
[
add
]
[
|
|
...
]